[1] |
I H,CHO J Y. Lung cancer biomarkers[J]. Adv Clin Chem,2015,72:107-170.
|
[2] |
STIEBER P,HATZ R,HOLDENRIEDER S, et al. National Academy of Clinical Biochemistry guidelines for the use of tumor markers in lung cancer[EB/OL].(2006-01-16)[2018-01-30]. .
|
[3] |
XU Y,XU L,QIU M, et al.Prognostic value of serum cytokeratin 19 fragments(Cyfra 21-1) in patients with non-small cell lung cancer[J]. Sci Rep,2015,5:9444.
|
[4] |
MARIAMPILLAI A I,CRUZ J P D,SUH J, et al. Cancer antigen 72-4 for the monitoring of advanced tumors of the gastrointestinal tract,lung,breast and ovaries[J]. Anticancer Res,2017,37(7):3649-3656.
|
[5] |
GREENBERG A K,LEE M S.Biomarkers for lung cancer: clinical uses[J]. Curr Opin Pulm Med,2007,13(4):249-255.
|
[6] |
FERRIGNO D,BUCCHERI G,GIORDANO C.Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer(NSCLC)[J]. Lung Cancer,2003,41(3):311-320.
|
[7] |
PUJOL J L,COOPER E H,LEHMANN M,et al.Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer[J]. Br J Cancer,1993,67(6):1423-1429.
|
[8] |
JÄRVISALO J,HAKAMA M,KNEKT P,et al. Serum tumor markers CEA,CA 50,TATI,and NSE in lung cancer screening[J]. Cancer,1993,71(6):1982-1988.
|
[9] |
WALOP W,CHRÉTIEN M,COLMAN N C,et al. The use of biomarkers in the prediction of survival in patients with pulmonary carcinoma[J]. Cancer,1990,65(9):2033-2046.
|
[10] |
ZHU Y,YANG Y,WANG Y,et al.Role of serum CA125 and CA199 concentration in diagnosis and prognosis evaluation of lung cancer patients[J]. Int J Clin Exp Pathol,2016,9(5):5388-5396.
|
[11] |
GRAVEY F,DAVY J B,GRANDHOMME F,et al.Serum tumor markers: comparison between guidelines and the clinical practice in a university hospital center[J]. J Clin Exp Pathol,2015,5:5-9.
|
[12] |
SCHNEIDER J.Tumor markers in detection of lung cancer[J]. Adv Clin Chem,2006,42:1-41.
|
[13] |
KULPA J,WÓJCIK E,REINFUSS M,et al. Carcinoembryonic antigen,squamous cell carcinoma antigen,CYFRA 21-1,and neuron-specific enolase in squamous cell lung cancer patients[J]. Clin Chem,2002,48(11):1931-1937.
|
[14] |
ARRIETA O,VILLARREAL-GARZA C,MARTÍNEZ-BARRERA L,et al. Usefulness of serum carcinoembryonic antigen(CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study[J]. BMC Cancer,2013,13:254.
|
[15] |
YU D,DU K,LIU T,et al.Prognostic value of tumor markers,NSE,CA125 and SCC,in operable NSCLC patients[J]. Int J Mol Sci,2013,14(6):11145-11156.
|
[16] |
万文徽,李吉友. 肿瘤标志的临床应用[J]. 中华医学检验杂志,1997,20(1):46-48.
|
[17] |
KIMURA Y,FUJII T,HAMAMOTO K, et al.Serum CA125 level is a good indicator in lung cancer[J]. Br J Cancer,1990,62(4):676-678.
|
[18] |
王赟,陈小东,张光明,等. 血清CA153在肺部良、恶性疾病鉴别诊断中的意义[J]. 中国癌症杂志,2002,12(1):45-47.
|
[19] |
梁红卫,孙玉汾. 血清CEA、CA199、CA125、CA153联检对肺癌的诊断价值[J]. 中国临床医学,2001,8(5):495-496.
|
[20] |
肖艳虹,伊晟,李曼,等. 肺癌相关肿瘤标志物检测的应用进展[J]. 国际检验医学杂志,2016,37(6):776-779.
|
[21] |
陈献,刘静莎,高红梅,等. 肺癌肿瘤标志物定量检测的临床价值[J]. 武警医学,2016,27(4):379-381.
|
[22] |
蔡静清,王宁. 多种肿瘤标志物联合检测在肺癌诊断中的应用价值[J]. 河北医学,2016,22(4):644-646.
|
[23] |
牛亚楠. 肺癌患者开展CEA、NSE与CYFRA21-1等肿瘤标志物检验的临床预测研究[J]. 首都食品与医药,2017,24(8):141-142.
|
[24] |
赵琳. 血清肿瘤标志物四种联合检测在肺癌早期诊断中的价值探讨[J]. 实用医技杂志,2017,24(5):510-512.
|
[25] |
舒媚,吴振兴,朱振亮,等. 血清肿瘤标志物联合检测在肺癌诊断中的价值[J]. 中华全科医学,2016,14(6):1019-1021.
|